Detection Rates of 68Ga-PSMA PET/CT in Patients with Biochemical Relapse from Prostate Cancer after Radical Prostatectomy and PSA Values < 1 ng/ml: Preliminary Results from a Prospective, Multicenter Trial

Julie Bødker Nielsen, Helle D Zacho, Katja Dettmann, Niels-Christian Langkilde, J. B. Jensen, Uwe Haberkorn, Lars J Petersen

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Resumé

PURPOSE: The aim of this study was to assess observer agreement on the evaluation of treatment responses of bone metastases by bone scintigraphy (BS) using different scoring methods in prostate cancer patients.

PATIENTS AND METHODS: Sixty-three paired BS from 55 patients were included. BS was performed before and after more than 12 weeks of anticancer treatment. A panel of experienced nuclear medicine physicians from several institutions evaluated treatment response using three different methods: (a) standard clinical assessment, (b) MD Anderson criteria, and (c) Prostate Cancer Working Group 2 (PCWG-2) criteria. All methods were based on the evaluation of paired before-after bone scans.

RESULTS: Readers were able to classify the presence of bone metastases at baseline with a high level of agreement [Cohen's κ=0.94, 95% confidence interval (CI) 0.82-1.00]. Observer agreement on bone response by PCWG-2 criteria showed considerable agreement (Cohen's κ=0.84, 95% CI: 0.69-0.99). Evaluation using standard clinical assessment and MD Anderson criteria showed moderate agreement (0.52, 95% CI: 0.36-0.69 and 0.64, 95% CI: 0.48-0.79, respectively). There was considerable variation among readers for regional lesion count on individual scans, with limits of agreement of -10 to 10 lesions or more for the majority of anatomical regions, including the thorax, spine, and pelvis.

CONCLUSION: Observer agreement on treatment response by BS varied notably across methods. Optimal agreement was achieved by the PCWG-2 criteria. Variation in the classification of treatment response of bone metastases may have a significant impact on clinical decision-making, emphasizing the need for a uniform approach, including during clinical practice. Response assessment by lesion counting on repeated BS without access to previous scans cannot be recommended.

OriginalsprogEngelsk
ArtikelnummerOP108
TidsskriftEuropean Journal of Nuclear Medicine and Molecular Imaging
Vol/bind43
Udgave nummerSuppl. 1
Sider (fra-til)S35
ISSN1619-7070
StatusUdgivet - 2016
BegivenhedAnnual Congress of the European Association of Nuclear Medicine - Barcelona, Spanien
Varighed: 5 okt. 201619 okt. 2016
http://www.eanm.org/congresses-events/past-congresses/congresses-overview/

Konference

KonferenceAnnual Congress of the European Association of Nuclear Medicine
LandSpanien
ByBarcelona
Periode05/10/201619/10/2016
Internetadresse

Fingerprint

Prostatectomy
Multicenter Studies
Prostatic Neoplasms
Bone and Bones
Recurrence
Radionuclide Imaging
Confidence Intervals
Neoplasm Metastasis
Therapeutics
Nuclear Medicine
Pelvis
Spine
Research Design
Thorax
Physicians

Citer dette

@article{f2325359f41c44a781419af587443b07,
title = "Detection Rates of 68Ga-PSMA PET/CT in Patients with Biochemical Relapse from Prostate Cancer after Radical Prostatectomy and PSA Values < 1 ng/ml: Preliminary Results from a Prospective, Multicenter Trial",
abstract = "PURPOSE: The aim of this study was to assess observer agreement on the evaluation of treatment responses of bone metastases by bone scintigraphy (BS) using different scoring methods in prostate cancer patients.PATIENTS AND METHODS: Sixty-three paired BS from 55 patients were included. BS was performed before and after more than 12 weeks of anticancer treatment. A panel of experienced nuclear medicine physicians from several institutions evaluated treatment response using three different methods: (a) standard clinical assessment, (b) MD Anderson criteria, and (c) Prostate Cancer Working Group 2 (PCWG-2) criteria. All methods were based on the evaluation of paired before-after bone scans.RESULTS: Readers were able to classify the presence of bone metastases at baseline with a high level of agreement [Cohen's κ=0.94, 95{\%} confidence interval (CI) 0.82-1.00]. Observer agreement on bone response by PCWG-2 criteria showed considerable agreement (Cohen's κ=0.84, 95{\%} CI: 0.69-0.99). Evaluation using standard clinical assessment and MD Anderson criteria showed moderate agreement (0.52, 95{\%} CI: 0.36-0.69 and 0.64, 95{\%} CI: 0.48-0.79, respectively). There was considerable variation among readers for regional lesion count on individual scans, with limits of agreement of -10 to 10 lesions or more for the majority of anatomical regions, including the thorax, spine, and pelvis.CONCLUSION: Observer agreement on treatment response by BS varied notably across methods. Optimal agreement was achieved by the PCWG-2 criteria. Variation in the classification of treatment response of bone metastases may have a significant impact on clinical decision-making, emphasizing the need for a uniform approach, including during clinical practice. Response assessment by lesion counting on repeated BS without access to previous scans cannot be recommended.",
author = "Nielsen, {Julie B{\o}dker} and Zacho, {Helle D} and Katja Dettmann and Niels-Christian Langkilde and Jensen, {J. B.} and Uwe Haberkorn and Petersen, {Lars J}",
year = "2016",
language = "English",
volume = "43",
pages = "S35",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Physica-Verlag",
number = "Suppl. 1",

}

Detection Rates of 68Ga-PSMA PET/CT in Patients with Biochemical Relapse from Prostate Cancer after Radical Prostatectomy and PSA Values < 1 ng/ml : Preliminary Results from a Prospective, Multicenter Trial. / Nielsen, Julie Bødker; Zacho, Helle D; Dettmann, Katja; Langkilde, Niels-Christian; Jensen, J. B.; Haberkorn, Uwe; Petersen, Lars J.

I: European Journal of Nuclear Medicine and Molecular Imaging, Bind 43, Nr. Suppl. 1, OP108, 2016, s. S35.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - Detection Rates of 68Ga-PSMA PET/CT in Patients with Biochemical Relapse from Prostate Cancer after Radical Prostatectomy and PSA Values < 1 ng/ml

T2 - Preliminary Results from a Prospective, Multicenter Trial

AU - Nielsen, Julie Bødker

AU - Zacho, Helle D

AU - Dettmann, Katja

AU - Langkilde, Niels-Christian

AU - Jensen, J. B.

AU - Haberkorn, Uwe

AU - Petersen, Lars J

PY - 2016

Y1 - 2016

N2 - PURPOSE: The aim of this study was to assess observer agreement on the evaluation of treatment responses of bone metastases by bone scintigraphy (BS) using different scoring methods in prostate cancer patients.PATIENTS AND METHODS: Sixty-three paired BS from 55 patients were included. BS was performed before and after more than 12 weeks of anticancer treatment. A panel of experienced nuclear medicine physicians from several institutions evaluated treatment response using three different methods: (a) standard clinical assessment, (b) MD Anderson criteria, and (c) Prostate Cancer Working Group 2 (PCWG-2) criteria. All methods were based on the evaluation of paired before-after bone scans.RESULTS: Readers were able to classify the presence of bone metastases at baseline with a high level of agreement [Cohen's κ=0.94, 95% confidence interval (CI) 0.82-1.00]. Observer agreement on bone response by PCWG-2 criteria showed considerable agreement (Cohen's κ=0.84, 95% CI: 0.69-0.99). Evaluation using standard clinical assessment and MD Anderson criteria showed moderate agreement (0.52, 95% CI: 0.36-0.69 and 0.64, 95% CI: 0.48-0.79, respectively). There was considerable variation among readers for regional lesion count on individual scans, with limits of agreement of -10 to 10 lesions or more for the majority of anatomical regions, including the thorax, spine, and pelvis.CONCLUSION: Observer agreement on treatment response by BS varied notably across methods. Optimal agreement was achieved by the PCWG-2 criteria. Variation in the classification of treatment response of bone metastases may have a significant impact on clinical decision-making, emphasizing the need for a uniform approach, including during clinical practice. Response assessment by lesion counting on repeated BS without access to previous scans cannot be recommended.

AB - PURPOSE: The aim of this study was to assess observer agreement on the evaluation of treatment responses of bone metastases by bone scintigraphy (BS) using different scoring methods in prostate cancer patients.PATIENTS AND METHODS: Sixty-three paired BS from 55 patients were included. BS was performed before and after more than 12 weeks of anticancer treatment. A panel of experienced nuclear medicine physicians from several institutions evaluated treatment response using three different methods: (a) standard clinical assessment, (b) MD Anderson criteria, and (c) Prostate Cancer Working Group 2 (PCWG-2) criteria. All methods were based on the evaluation of paired before-after bone scans.RESULTS: Readers were able to classify the presence of bone metastases at baseline with a high level of agreement [Cohen's κ=0.94, 95% confidence interval (CI) 0.82-1.00]. Observer agreement on bone response by PCWG-2 criteria showed considerable agreement (Cohen's κ=0.84, 95% CI: 0.69-0.99). Evaluation using standard clinical assessment and MD Anderson criteria showed moderate agreement (0.52, 95% CI: 0.36-0.69 and 0.64, 95% CI: 0.48-0.79, respectively). There was considerable variation among readers for regional lesion count on individual scans, with limits of agreement of -10 to 10 lesions or more for the majority of anatomical regions, including the thorax, spine, and pelvis.CONCLUSION: Observer agreement on treatment response by BS varied notably across methods. Optimal agreement was achieved by the PCWG-2 criteria. Variation in the classification of treatment response of bone metastases may have a significant impact on clinical decision-making, emphasizing the need for a uniform approach, including during clinical practice. Response assessment by lesion counting on repeated BS without access to previous scans cannot be recommended.

M3 - Conference abstract in journal

VL - 43

SP - S35

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - Suppl. 1

M1 - OP108

ER -